MIRASOL: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF MIRVETUXIMAB SORAVTANSINE VS. INVESTIGATOR'S CHOICE OF CHEMOTHERAPY IN ADVANCED HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS WITH HIGH FOLATE RECEPTOR-ALPHA EXPRESSION
- Registry ID
- IMGN853-0416
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- IMMUNOGEN INC
- Start date
- 2020-11-09
- Last update
- 2020-02-19
Conditions
- PRIMARY PERITONEAL CANCER
- EPITHELIAL OVARIAN CANCER
- FALLOPIAN TUBE CANCER
Related clinical trials
- A PHASE 1B/2 OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF RALUDOTATUG DERUXTECAN WITH OR WITHOUT OTHER ANTICANCER INVESTIGATIONAL AGENTS IN PARTICIPANTS WITH HIGH-GRADE SEROUS EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCER WHO HAVE RELAPSED AFTER PRIOR PLATINUM-BASED CHEMOTHERAPY
- A RANDOMISED, OPEN-LABEL, PHASE III STUDY OF AZD5335 VERSUS MIRVETUXIMAB SORAVTANSINE IN FR¿-HIGH AND AZD5335 VERSUS INVESTIGATOR’S CHOICE CHEMOTHERAPY IN FR¿-LOW EXPRESSING HIGH-GRADE PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER PATIENTS (TREVI-OC-01)
- A PHASE 1, FIRST-IN-HUMAN, OPEN-LABEL, DOSE-ESCALATION AND EXPANSION STUDY OF
IMGN151 (ANTI-FR¿ ANTIBODY-DRUG CONJUGATE) IN ADULT PATIENTS WITH RECURRENT
ENDOMETRIAL CANCER AND RECURRENT, HIGH-GRADE SEROUS EPITHELIAL OVARIAN,
PRIMARY PERITONEAL, OR FALLOPIAN TUBE CANCERS
- A PHASE 2 OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF LUVELTAMAB TAZEVIBULIN (STRO-002) IN WOMEN WITH RELAPSED PLATINUM-RESISTANT EPITHELIAL OVARIAN CANCER (INCLUDING FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCERS) EXPRESSING FOLATE RECEPTOR ALPHA (FOLR1)
- A PHASE 3 STUDY OF RELACORILANT IN COMBINATION WITH NAB-PACLITAXEL VERSUS NAB-PACLITAXEL MONOTHERAPY IN ADVANCED, PLATINUM-RESISTANT HIGH-GRADE EPITHELIAL OVARIAN, PRIMARY PERITONEAL, OR FALLOPIAN-TUBE CANCER (ROSELLA)
- 68GA-FAPI PET/CT IN THE STAGING OF HIGH GRADE EPITHELIAL OVARIAN CANCERS: A PILOT STUDY
View on source registry